Evaluation of immune function under conversion from Prograf to Advagraf in living donor liver transplantation

Annals of Transplantation

Volumn 18, Issue 1, 2013, Pages 293-298

  Tanaka, Takayuki ^a   Takatsuki, Mitsuhisa ^a   Soyama, Akihiko ^a   Torashima, Yasuhiro ^a   Kinoshita, Ayaka ^a   Yamaguchi, Izumi ^a   Adachi, Tomohiko ^a   Kitasato, Amane ^a   Kuroki, Tamotsu ^a   Eguchi, Susumu ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Advagraf; ImmuKnow; LDLT; Tacrolimus

Indexed keywords

ADENOSINE TRIPHOSPHATE; BILIRUBIN; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUKNOW ASSAY; IMMUNITY; KIDNEY FUNCTION; LABORATORY TEST; LIVER FUNCTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; QUANTITATIVE ASSAY;

ADENOSINE TRIPHOSPHATE; ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; DELAYED-ACTION PREPARATIONS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; TACROLIMUS; TRANSPLANTATION IMMUNOLOGY; YOUNG ADULT;

EID: 84887229791     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.883953     Document Type: Article

References (21)

1. Chapman JR: The KDIGO clinical practice guideline for the care of kidney transplant recipients. Transplantation, 2010; 89: 644-45
2. Weiler N, Thrun I, Hoppe-Lotichius M et al: Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. Transplantation, 2010; 90: 1562-66
3. Gaston RS, Hudson SL, Ward M et al: Late renal allograft loss: noncompliance masquerading as chronic rejection. Transplant Proc, 1999; 31: 21S-23S
4. Denhaerynck K, Dobbles F, Cleemput I et al: Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review. Transpl Int, 2005; 18: 1121-33
5. van Hooff JP, Alloway RR, Trunečka P, Mourad M: Four-year experience with tacrolimus oncedaily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. Clin Transplant, 2010; 25: E1-12
6. Iaria G, Sforza D, Angelico R et al: Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation. Transplant Proc, 2011; 43: 1028-29
7. Calia R, Lai C, Aceto P et al: Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation. Transplant Proc, 2011; 43: 1020-23
8. Marin-Gomez LM, Gomez-Bravo MA, Alamo-Martinez JA et al: Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. Transplant Proc, 2009; 41: 2184-86
9. Trunečka P, Boillot O, Seehofer D et al: Oncedaily prolonged-release tacrolimus (ADVAGRAF) versus twice-dailiy tacrolimus (PROGRAF) in liver transplantation. Am J Transplant, 2010; 10: 2313-23
10. Comuzzi C, Lorenzin D, Rossetto A et al: Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients. Transplant Proc, 2010; 42: 1320-21
11. Perrakis A, Schwarz K, Yedibela S et al: Impact of the conversion of the immunosuppressive regimen from Prograf to Advagraf or to Sirolimus in long-term stable liver transplant recipients: indication, safety, and outcome. Transplant Proc, 2011; 43: 3702-7
12. Kowalski RJ, Post DR, Schneider MC et al: Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant, 2003; 17: 77-88
13. Kowalski RJ, Post DR, Mannon RB et al: Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006; 82: 663-68
14. Sottong PR, Rosebrock JA, Britz JA, Kramer TR: Measurement of T-lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin Diagh Lab Immunol, 2000; 7: 307-11
15. O'Carroll RE, McGregor LM, Swanson V et al: Adherence to medication after liver transplantation in Scotland: a pilot study. Liver Transplant, 2006; 12: 1862-68
16. Butler JA, Roderick P, Mullee M et al: Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation, 2004; 77: 769-76
17. Vasquez EM, Tanzi M, Benedetti E, Pollak R: Medication noncompliance after kidney transplantation. Am J Health Syst Pharm, 2003; 60: 266-69
18. Kelly PA, Burckart GJ, Venkataramanan R: Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm, 1995; 52: 1521-35
19. Spencer CM, Goa KL, Gillis JC: Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs, 1997; 54: 925-75
20. Morrissey PE, Flynn ML, Lin S: Medication noncompliance and its implications in transplant recipients. Drugs, 2007; 67: 1463-81
21. Weng FL, Israni AK, Joffe MM et al: Race and electronically measured adherence to immunosuppressive medications after decreased donor renal transplantation. J Am Soc Nephrol, 2005; 6: 1839-48